Because pituitary GH release is inhibited by GIH and hypothalamic secretion of this peptide seems to be mainly dependent on O-adrenergic regulation,we have investigated if BAB could modify the pattern of GH response to 2F; .6 y) and lF; .Blood samples for GH where collected from -15'to+ 60'according the following tests: A)Propranolol(1 mg/kg,as iv bolus at -6O8);B)CRF(1 mcg/kg,as iv bolus at O');C)Propranolol(as in A)+GRF(as in B).RESULTS(X*SD): C)1.4* -6 1.7t.5 49.7f25.3*61.9*18* 39.8210* 28.2+ 5.2 IGH-DA)1.2+ .3 1.3t.2 2.1f .9 2.5? .7 2.3+ 1.1 2.22 .6 B) . 9+ .5 .92.7 21.5t 7.8*25.9f13.2 18.1216 13.2t 9.1 c)i.3t .5 1.4t.2 32.iri9.2*38.9*14.6 25.7*17 15.1*11.9 BAB produced a significant GH release in SN but not in IGH-D. Also,while GH response to GRF was similar in SN and IGH-D,previous BAB did increase the amplitude and latency of this response only in SN.Both facts lead us to speculate that an increased somatostatinergic tone could be the cause of short stature in some short-normal children.*pc0.02 vs O:*pc0.02 vs testB. height velocity and partial GH deficiency in response to two pharmacological tests (maximum peak 11 ng/ml) received GRF for 6 months (10 mcg/kg/day) as a subcutaneous injection ( 8 p.m.). 24-hours GH secretion was studied before and after 3 months of treatment : SmC dosage and a IV GRF test (2 mcg/kg) was done before and after 6 months of treatment. Lower leg length was studied every 3 weeks by knemometry and statural growth at 3 months intervals.
Height velocity increased in 5 cases from 2.5 + 0.5 to 4.4 1.1 cm for the 6 months period and showed no change in 2 cases. Knemometric growth rate is subject to wide variations and is difficult to take into account. There was no sign of desensitization: 24-hour secretion (mx peak and I.C.) was higher after 3 months treatment (m = 16.2 + 7.5 ng/ml and 3.7 2 1.2 ng/ml/min before, 29 2 17.9 ng/ml and 4.5 + 2.9 ng/ml/mln afterwards), as was the GH peak in the IV GRF test after 6 months treatment (m = 36.1 ng/ml before, 47.8 ng/ml afterwards). SmC level was higher on average after 6 months treatment (1.9 2 1 U/ml and 0.8 2 0.5 U/ml before treatment). The analysis of the varlous parameters (GH secretion, SrnC) provided no elements to account for the lack of therapeutic response in the 2 cases. These results suggest that GRF treatment
5 children (8.24+/-3.63 years) with growth retardation (3.4 +/-0.9 DS)bone age retardation (3.13+/-2.40 years) and insufficient growth velocity (3.9+/-0.6 cmlyear) related with complete (n=2) or partial (n=3) GH deficiency were treated with a daily dose of 300 mcg GRF administred subcutaneously (%)every other week for a 6 months period. GH response to SC GRF administration, GH and GRF antibodies and somatomedins were studied on repeated blood samples performed on day I and day 8 of the first week of treatment as well as at the end of the 6 months therapy. Growth velocity increased to 6.16+/-1.17 cm/year. 3 of the 5 patients have accelerated growth mainly for the first 3 months. Linear growth was increased in complete (+2.5 and 4.3 cmlyear) more than in partial (+0.4, +0.8 and +3.3 cmlyear) GB deficient children. The area under the GH curve after GRF administration was 1050.7+/-767.7 on day 1, 472.1+/-103.2 on day 8 and 631.9 91-148.1 ng/ml x min. after 6 months therapy. No major change in other hormonal evaluations was noted. These results confirm that GRF can stimulate linear growth in some GH deficient children and lead to discuss the role of limiting factors in its long term effects such as desensitization, antibodies or somatostatin. P.J.SMITH*, C.G.D.BROOK
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PULSATILE GROWTH HORMONE RELEASING HORMONE TREATMENT OF GH DEFICIENCY
We have treated 1 1 prepubertal children (7M;4F) with idiopathic GH deficiency due to pituitary hypoplasia using GHRH 1-40. This was administered subcutaneously for 4 pulses at 3 hourly intervals at night in a dose of I-2vg/kg/pulse. Blood samples for GH concentrations were taken at 20 minute intervals for 24 hours before treatment and throughout the study monthly at night.
Pulsatile GH secretion was induced in 10 children from the first night of treatment and the response augmented with time. Growth velocity in 8 of 1 1 children increased from 3.3cmlyr (range 1.7 to 4.9) before treatment to 6.9cmIyr (range 5-8.5) on GHRH. 2 children had no change in height velocity and one had a progressive diminution of GH secretion and a fall in growth velocity.
GHRH (lpg/kg) was also administered intravenously to all children before treatment and at 3 monthly intervals. Although a GH response was seen on all occasions, the responses predicted neither the GH concentrations nor the growth velocities obtained on long term s.c. treatment.
Pulsatile administration of GHRH 1-40 was effective in inducing GH secretion and promoting growth acceleration in the majority of children with idiopathic GH deficiency. may be considered as a therapeutic alternative in GH deficienc~es. 
INSULIN-LIKE GROWTH FACTOR I
n7e biochfmical and @w&h mpm%zs t o CWW(1-2'1)NlG therapy were studied in 18 preplbertal CH-deficient children (14 idiopathic, 3 cranial irradiation, 1 septooptic dysplasia; 16 male, 2 fenale, mean ap;F 9.5 years, r a~~ 6.e -14.2 years). (3 deficiency was defined as a p?ak C+i to stindation of less than 7 nhl/l. Fwrteen children had received i %Y treatmnt which was stopped at least 3 rmnths before We trial. CHW1 was given as M c e daily sc inject.icm in individual doses of 250 pg (childrm less th% 20 kg bw), and 500 pg ( p t e r than 20 kg). Peak s e m Gal respw to BW1 before t m t m n t was 25.8 + 6.3 mU/1 (man + SE) and after 3 rmnths 27.4 + 4.2 n W 1 ; indicating ra desemitisation effect. 'Ihirteen of the 1 8 shewed an i n c m n t in h e m t velocity after 3 nantk therapy, in 6 this was greater Wan 2 m/year and i n 3 p t e r t h 5 an/year.
'Ihree childm sh3wed a W t e r height velocity on BW1 than on KX. Ei&t children have amplet& 6 mnths therapy and 3 M e shown an i n c m n t in h e w t velocity of 0.4, 2.5, and 3.1 m/year. W r e was ro cornlation b e m n the gm&h r e s p n s e at 3 rmnths and p~treatrent 81 mpme to BW1. In oonclusion, we have shm~ U?at M c e daily sc BW1 therapy i s a safe treawnt which p m t e d linear p m t h at 3 rmnths i n 13 of 1 8 Ql-deficient children. fhever, predictors of @ gtowth mpnses cwld m t be identified.
Starting from Cohn fraction IV of human plasma we earlier described a multiple step procedure which resulted in ug amount of IGF I/SmC of relative high purity (200 pU/vg)+. In the meanwhile we have further modified this method: 20 grs. of acetone dried Cohn fraction IV are suspended in 1% NaCl/fornic acid, pH 3.0. After precipitation of the IGF I containing proteins in the supernatant by addition of 5 M NaCl the precipitate is resuspended in 2 N acetic acid (AA) /ethanol (1:4). Denatured proteins are discarded by centrifugation, and after evaporation the supernatant is chromatographed on Sephadex G 50 in 1 N AA.
IGF I containing fractions (approx. 12 pg IGF I, purity of approx. 90%) are purified by 1mmobilineR isoelectric focusing (IEF) (pH 8-10). The IGF I band, focusing at pH 8.3 finally is purified using a HPLC reversed phase C-18 column in a 25-65% acetonitrile gradient cont. 0.05% TFA. IGF I elutes in a single peak at approx. Res. 18, 107 (1984) 
